Company intelligence / Profile preview

AK BioPharm

Ulsan, Ulsan, South Korea

Ownership: Private
Development stage: Other

Overview

AK BioPharm is a world leader in manufacturing high-purity Omega‑3 active pharmaceutical ingredients (APIs), focusing on EPA and DHA separation and concentration up to 97% using proprietary Vacuum Fraction Distillation and HPLC technologies under GMP regulations. Their APIs have received regulatory approvals from KFDA, PMDA, and DMF filings for use in pharmaceuticals and dietary supplements[1][2][3][5].

Therapeutic areas: Metabolic Disorders
Modalities: Small moleculeFish oil-derived biologicOmega fatty acid derivative
Industry: Contract Manufacturing Organization

Partnerships

Previously partnered with Maruha Nichiro Corporation of Japan until September 2022[5].

Beyond the preview

Go deeper on AK BioPharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK BioPharm.

Explore the full profile